IGC Pharma (IGC) announced a clinical trial site at Santa Cruz Behavioral in Puerto Rico for its CALMA Phase 2 clinical trial, investigating IGC-AD1 for agitation in Alzheimer’s disease. This strategic site directly addresses the significant impact of Alzheimer’s in the region.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IGC:
- IGC Pharma presents genetic toxicology safety data on IGC-AD1
- IGC Pharma announces strategic investment from advisors
- IGC Pharma expands CALMA trial with addition of Butler Hospital Program
- IGC Pharma announces CALMA Phase 2 trial expansion with Miami Jewish Health
- IGC Pharma expands CALMA clinical trial